摘要
目的:观察卡维地洛联合缬沙坦治疗重症慢性心力衰竭(CHF)患者的效果。方法:选取102例重症CHF患者为研究对象,按照随机数字表法分为对照组和研究组各51例。对照组采取缬沙坦治疗,研究组在对照组基础上联合卡维地洛治疗,比较两组临床疗效、治疗前后心功能指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)]水平、血小板活化因子(PAF)水平、血清卵泡抑素样蛋白1(FSTL-1)水平及不良反应发生率。结果:研究组治疗总有效率为96.08%,高于对照组的84.31%,差异有统计学意义(P<0.05);治疗后,研究组LVEF水平高于对照组,LVEDD、LVESD水平均低于对照组,差异有统计学意义(P<0.05);治疗后,研究组PAF、FSTL-1水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:卡维地洛联合缬沙坦治疗重症CHF患者,可提高临床疗效,改善心功能指标水平,降低PAF和FSTL-1水平,且安全性高,其效果优于单纯缬沙坦治疗。
Objective:To observe effects of Carvedilol combined with Valsartan in treatment of patients with severe chronic heart failure(CHF).Methods:102 severe CHF patients were selected as the research objects and were divided into control group and study group according to the random number table method,51 cases in each group.The control group was treated with Valsartan,while the study group was treated with Carvedilol on the basis of that of the control group.The clinical effects,the cardiac function index levels[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)],the platelet-activating factor(PAF)level,the serum Follistatinlike protein 1(FSTL-1)level and incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 96.08%,which was higher than 84.31%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the level of LVEF in the study group was higher than that in the control group;the levels of LVEDD and LVESD were lower than those in the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of PAF and FSTL-1 in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Carvedilol combined with Valsartan in the treatment of the severe CHF patients can improve clinical effects,improve the cardiac function index levels,and reduce the PAF and FSTL-1 levels with high safety.Moreover,it is superior to single Valsartan treatment.
作者
李巧
LI Qiao(Department of Cardiovascular Medicine of the 7th People’s Hospital of Zhengzhou,Zhengzhou 450000 Henan,China)
出处
《中国民康医学》
2022年第7期35-37,41,共4页
Medical Journal of Chinese People’s Health
关键词
卡维地洛
缬沙坦
重症慢性心力衰竭
心功能
血小板活化因子
卵泡抑素样蛋白
不良反应
Carvedilol
Valsartan
Severe chronic heart failure
Cardiac function
Platelet activating factor
Follistatin-like protein
Adverse reaction
